Monarch: A Platform for Logic Optimization using ATPG/Diagnosis-based Design Rewiring

In a typical VLSI design cycle, technology-dependent logic optimization may occur after the physical synthesis to satisfy various design constraints in area, power, timing, and testability. Recently, it is proposed in [7] an ATPGbased design rewiring methodology that achieves significant performance gains in benchmark circuits that are already optimized by formal techniques. This case study describes an application of this technique as a logic optimization platform for Motorola high-performance designs: Monarch. The flow, which consists of EDA vendor tools and inhouse software, allows the design error diagnosis and correction techniques of [7] to be applied to gate-level modules in high-performance cores. Experiments in timing optimization show that Monarch can improve the slack of a module that has been already optimized by tools from commercial EDA vendors. 1

Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.

Dostarlimab is an anti-programmed cell death protein-1 antibody being evaluated in recurrent/advanced solid tumors, including non-small cell lung cancer (NSCLC), in the ongoing Phase I, multi-center, open-label, 2-part (dose escalation and cohort expansion) GARNET study (NCT02715284). Here, we report an interim analysis of patients with recurrent/advanced NSCLC who progressed following platinum-based chemotherapy. Patients received dostarlimab (500 mg IV every 3 weeks [Q3W] for Cycles 1-4, then 1000 mg Q6W) until disease progression or unacceptable toxicity for > 2 years. The primary endpoints were immune-related objective response rate (irORR) per investigator-assessed irRECIST and safety. As of 8, July 2019, 67 patients with recurrent/advanced NSCLC were enrolled and treated with dostarlimab; the majority had programmed death ligand 1 (PD-L1) tumor proportion score (TPS) Dostarlimab demonstrated promising antitumor activity in advanced/recurrent NSCLC that progressed following platinum-based chemotherapy, including across all PD-L1 subgroups, and has an acceptable safety profile